Survey of Ophthalmology
Volume 47, Issue 1 , Pages 68-73 , January 2002

II. Choosing Beta-Blockers for Initial Medical Therapy For Glaucoma

  • Stephen A Wigginton, MD
    • ,
  • Eve J Higginbotham, MD

      Affiliations

    • Corresponding Author InformationReprint address: Eve J. Higginbotham, MD, Department of Ophthalmology, University of Maryland School of Medicine, 419 W. Redwood Street Suite 580, Baltimore, MD 21201

References 

  1. Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol. 1991;75:519–523
  2. Allen RC. Medical treatment of open angle glaucoma. In:  Weinstein G editors. Open Angle Glaucoma. Boston: Little Brown; 1985;, p 31
  3. Alward WL. Medical management of glaucoma. N Engl J Med. 1998;339:1298–1307
  4. Beasley H, Fraunfelder FT. Retinal detachments and topical ocular miotics. Ophthalmology. 1979;86:95–98
  5. Boger WP. Shortterm escape and longterm drift. The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28(Suppl):235–242
  6. Brown SM. Increased iris pigment in a child due to latanoprost. Arch Ophthalmol. 1998;116:1683–1684
  7. Butler P, Mannschreck M, Lin S, et al.  Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113:293–296
  8. Carlsen JO, Zabriskie NA, Kwon YH, et al.  Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol. 1999;128:255–256
  9. Diggory P, Cassels-Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. Br J Ophthalmol. 1998;82:146–149
  10. Diggory P, Franks W. Glaucoma (systemic side effects of topical medical therapy—a common and under recognized problem). J R Soc Med. 1994;87:575–576
  11. Fiscella RG. Costs of glaucoma medications. Am J Health Syst Pharm. 1998;55:272–275
  12. Fiscella RG, Geller JL, Gryz LL, et al.  Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128:426–433
  13. Fraunfelder FT, Meyer SM, Bagby GC, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985;100:79–81
  14. Gross RL, Hensley SH, Gao F, Wu SM. Retinal ganglion cell dysfunction induced by hypoxia and glutamate (potential neuroprotective effects of beta-blockers). Surv Ophthalmol. 1999;43(Suppl 1):S162–S170
  15. Gross RL, Pinyero A, Orengo-Nania S. Clinical experience with apraclonidine 0.5%. J Glaucoma. 1997;6:298–302
  16. Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301–309
  17. Higginbotham EJ. Initial treatment for open-angle glaucoma- medical, laser or surgical? Medication is the treatment of choice for chronic open-angle glaucoma. Arch Ophthalmol. 1998;116:239–240
  18. Kass MA, Meltzer DW, Gordon M, et al.  Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523
  19. Konowal A, Morrison JC, Brown SV, et al.  Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403–406
  20. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group. 1998;2.(Ophthalmology 105):1960–1967
  21. Miyake K, Ota I, Maekubo K, et al.  Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34–40
  22. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al.  Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024–1029
  23. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol. 1987;31:307–327
  24. Osborne NN, Ugarte M, Chao M, et al.  Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43(Suppl 1):S102–S128
  25. Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097–1106
  26. Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol. A new drug for management of chronic simple glaucoma. Arch Ophthalmol. 1978;96:1003–1008
  27. Robin AL. Questions concerning the role of apraclonidine in the management of glaucoma. Arch Ophthalmol. 1995;113:712–714
  28. Rosenlund EF. The intraocular pressure lowering effect of timolol in gel-forming solution. Acta Ophthalmol Scand. 1996;74:160–162
  29. Schnyder CC, Tran VT, Mermoud A, Herbort CP. Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops. Arch Ophthalmol. 1999;117:1429–1431
  30. Schuman JS. Antiglaucoma medications (a review of safety and tolerability issues related to their use). Clin Ther. 2000;22:167–208
  31. Schwartz B, Lavin P, Takamoto T, et al.  Decrease of optic disc cupping and pallor of ocular hypertensives with timolol therapy. Acta Ophthalmol Scand (Suppl). 1995;73:5–21
  32. Schwartz B, Takamoto T, Lavin P. Increase of retinal vessel width in ocular hypertensives with timolol therapy. Acta Ophthalmol Scand (Suppl). 1995;73:41–53
  33. Schwartz B, Takamoto T, Lavin P, Smits G. Increase of retinal nerve fiber layer thickness in ocular hypertensives with timolol therapy. Acta Ophthalmol Scand (Suppl). 1995;73:22–32
  34. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 1998;126:400–408
  35. Stewart WC, Day DG, Sharpe ED, et al.  Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol. 1999;128:692–696
  36. Stewart WC, Dubiner HB, Mundorf TK, et al.  Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol. 1999;127:142–147
  37. Stewart WC, Osterman J. Serum lipid physiology and the influence of glaucoma medications. Surv Ophthalmol. 1998;43:233–244
  38. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113:1009–1016
  39. Sudesh S, Cohen EJ, Rapuano CJ, Wilson RP. Corneal toxicity associated with latanoprost. Arch Ophthalmol. 1999;117:539–540
  40. Tasindi E, Talu H. Differential effect of betaxolol and timolol on the progression of glaucomatous visual field loss (a four year prospective study, in Drance S: Vascular Risk Factors and Neuroprotection in Glaucoma: Update). Amsterdam: Kugler Publications; 1996;
  41. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315–1319
  42. United States Pharmacopeial Convention, Inc.: United States Pharmacopeial Drug Index. Englewood, CO, Micromedex, Thomson Healthcare, 2001
  43. Vold SD, Wiggins DA, Jackimiec J. Cost analysis of glaucoma medications. J Glaucoma. 2000;9:150–153
  44. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997;115:1206–1208
  45. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602–604
  46. Wandel T, Fishman D, Novack GD, et al.  Ocular hypotensive efficacy of 0.25% levobunolol instilled once daily. Ophthalmology. 1988;95:252–255
  47. Warwar RE, Bullock JD. Latanoprost-induced uveitis. Surv Ophthalmol. 1999;43:466–468
  48. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138
  49. Wu DC, Schwartz B, Schwoerer J, Banwatt R. Retinal blood vessel width measured on color fundus photographs by image analysis. Acta Ophthalmol Scand. 1995;73(Suppl):33–40
  50. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601–604

☆ The authors have no commercial or proprietary interest in any product or concept discussed in this article. Supported in part by a grant from Research to Prevent Blindness, New York, NY.

PII: S0039-6257(01)00287-9

Survey of Ophthalmology
Volume 47, Issue 1 , Pages 68-73 , January 2002

Article Tools